因塞特 INCY 深 沪
已收盘 08-07 16:00:00 美东时间
120.56
+2.180
+1.84%
华盛通- 最 高124.57
- 今 开118.56
- 成交量 148.05万股
- 最 低 115.77
- 昨 收 118.38
- 总市值 2676.43万
- 52周最高 132.60
- 市盈率 静 28.22
- 换手率 666.88%
- 52周最低 81.09
- 委 比 -12.72%
- 总股本 0.00亿
- 历史最高 153.15
- 量 比 0.76
- 振 幅 7.43%
- 历史最低 1.10
- 每 手 1
- 风险率 10.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Incyte Says It's No Longer A One-Drug Story
Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.
07-29 03:10
This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts upgraded APA, INCY, COP, OVV, BWXT stocks with higher price targets. Check out what other analysts think before buying COP.
06-22 20:31
BMO Capital Upgrades Incyte to Market Perform, Raises Price Target to $94
BMO Capital analyst Evan Seigerman upgrades Incyte (NASDAQ:INCY) from Underperform to Market Perform and raises the price target from $75 to $94.
06-22 17:22
Incyte Strikes Agreement To Acquire Vega Therapeutics For $1.25B
Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be
06-08 19:20
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts
Throughout the last three months, 13 analysts have evaluated Incyte (NASDAQ:INC...
03-09 20:00
Incyte Sees FY26 Net Product Revenue Of $4.77B-$4.94B
2026 Financial GuidanceIncyte's guidance for the fiscal year 2026 is summarized below. Total net product revenue guidance of $4,770 to $4,940 million comprises: Jakafi net product revenue of $3,220 to $3,270 million and
02-10 20:03
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
01-12 18:47
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.
01-06 00:59
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook.
2025-10-29 02:44
Earnings Scheduled For October 28, 2025
Companies Reporting Before The Bell • PayPal Holdings (NASDAQ:PYPL) is expected...
2025-10-28 19:11
